[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:skin-squamous-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":280,"states":292},"Skin Squamous Cell Carcinoma",44,38,[8,16,22,29,36,42,48,55,62,68,74,80,87,93,99,105,111,117,123,129,135,141,147,153,159,165,171,177,182,188,194,200,206,212,218,224,229,235,241,248,255,262,268,274],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07042295","Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System",[12],"Phase 2","RECRUITING","2026-08-26T02:18:51.009190Z","2026-07-30T01:46:14.416541Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07228442","L19IL2\u002FL19TNF in Patients With Cutaneous Squamous Cell Carcinoma",[12],"2026-08-26T02:15:28.524219Z","2026-07-24T01:27:14.896562Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06585410","Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",[26],"Phase 3","2026-08-26T02:16:21.385056Z","2026-07-05T05:32:16.760741Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04975152","Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma",[33],"Phase 1","2026-08-26T02:18:02.701182Z","2026-05-29T15:36:40.162110Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06998342","MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer",[12],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:29.493293Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06567314","Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:29.051413Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT06664151","A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision",[52],"Early Phase 1","2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.795019Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":60,"content_modified":61},"NCT05377905","Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)",[59],"Phase 1\u002FPhase 2","2026-08-26T02:15:04.877798Z","2026-05-05T02:43:28.659876Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT07288073","TIL Therapy in cSCC and MCC",[12],"2026-08-26T02:18:58.958025Z","2026-05-05T02:43:28.659766Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT06990737","Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck",[12],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:28.420210Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05085496","Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC",[33],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:27.659509Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":85,"content_modified":86},"NCT07426484","Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy",[84],"Phase 4","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:27.170378Z",{"nct_id":88,"title":89,"phases":90,"status":13,"updated_at":91,"content_modified":92},"NCT04428671","Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer",[33],"2026-08-26T02:17:58.890423Z","2026-05-05T02:35:31.710132Z",{"nct_id":94,"title":95,"phases":96,"status":13,"updated_at":97,"content_modified":98},"NCT06171750","Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors",[33],"2026-08-26T02:14:59.425132Z","2026-05-05T02:43:28.000345Z",{"nct_id":100,"title":101,"phases":102,"status":13,"updated_at":103,"content_modified":104},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[59],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":106,"title":107,"phases":108,"status":13,"updated_at":109,"content_modified":110},"NCT07602842","A Study of IDP-001 in Advanced or Metastatic Solid Tumors",[59],"2026-08-26T02:17:12.307088Z","2026-05-29T15:36:40.222864Z",{"nct_id":112,"title":113,"phases":114,"status":13,"updated_at":115,"content_modified":116},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[33],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.735881Z",{"nct_id":118,"title":119,"phases":120,"status":13,"updated_at":121,"content_modified":122},"NCT06444815","A Study of VET3-TGI in Patients With Solid Tumors",[33],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.507169Z",{"nct_id":124,"title":125,"phases":126,"status":13,"updated_at":127,"content_modified":128},"NCT05267626","Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",[59],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:28.878293Z",{"nct_id":130,"title":131,"phases":132,"status":13,"updated_at":133,"content_modified":134},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[33],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":136,"title":137,"phases":138,"status":13,"updated_at":139,"content_modified":140},"NCT07217171","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas",[33],"2026-08-26T02:16:38.053590Z","2026-05-05T02:43:28.073966Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":145,"content_modified":146},"NCT04370587","A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors",[59],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:27.914403Z",{"nct_id":148,"title":149,"phases":150,"status":13,"updated_at":151,"content_modified":152},"NCT05859074","A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",[33],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.807952Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":157,"content_modified":158},"NCT04429542","Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",[33],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.748848Z",{"nct_id":160,"title":161,"phases":162,"status":13,"updated_at":163,"content_modified":164},"NCT06960395","Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",[33],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:27.743517Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":169,"content_modified":170},"NCT06090266","A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents",[59],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.247900Z",{"nct_id":172,"title":173,"phases":174,"status":13,"updated_at":175,"content_modified":176},"NCT05969860","At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer",[12],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:26.978986Z",{"nct_id":178,"title":179,"phases":180,"status":13,"updated_at":121,"content_modified":181},"NCT05725291","AMT-116 in Patients With Advanced Solid Tumors",[33],"2026-05-05T02:43:26.924853Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT04389632","A Study of Sigvotatug Vedotin in Advanced Solid Tumors",[33],"2026-08-26T02:19:16.454910Z","2026-05-05T02:35:31.860308Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT05086692","A Beta-only IL-2 ImmunoTherapY Study",[59],"2026-08-26T02:18:31.164304Z","2026-05-05T02:35:31.708594Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT05896839","Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",[59],"2026-08-26T02:19:11.399072Z","2026-05-05T02:35:31.620913Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[59],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT06177106","SUV PDL1\u002FPD1 in Sun Damaged & Sun Protected Human Skin of Participants",[],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.119238Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT07286318","A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients",[52],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.065852Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT05108090","Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck",[],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.207881Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":109,"content_modified":228},"NCT06875609","ctDNA in Cutaneous Squamous Cell Carcinoma",[],"2026-05-13T02:55:06.587207Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06606028","Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma",[],"2026-08-26T02:15:42.447052Z","2026-05-13T02:55:06.554244Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT07339176","Intratumoral N17350 in Advanced Solid Tumors",[59],"2026-08-26T02:15:33.331531Z","2026-07-19T19:36:05.138081Z",{"nct_id":242,"title":243,"phases":244,"status":245,"updated_at":246,"content_modified":247},"NCT07715734","Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:51.982021Z","2026-07-24T01:27:14.913150Z",{"nct_id":249,"title":250,"phases":251,"status":252,"updated_at":253,"content_modified":254},"NCT06782399","Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma",[52],"ENROLLING_BY_INVITATION","2026-08-26T02:17:07.954622Z","2026-06-16T05:54:07.770961Z",{"nct_id":256,"title":257,"phases":258,"status":259,"updated_at":260,"content_modified":261},"NCT06580054","Pembrolizumab for the Treatment of Locally Advanced and\u002For Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:05:54.503205Z","2026-05-05T02:43:29.048394Z",{"nct_id":263,"title":264,"phases":265,"status":259,"updated_at":266,"content_modified":267},"NCT05070403","Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma",[12],"2026-08-03T02:54:41.410572Z","2026-05-05T02:43:28.839280Z",{"nct_id":269,"title":270,"phases":271,"status":259,"updated_at":272,"content_modified":273},"NCT05323253","A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma",[],"2026-08-03T03:09:30.306745Z","2026-05-05T02:43:26.963180Z",{"nct_id":275,"title":276,"phases":277,"status":259,"updated_at":278,"content_modified":279},"NCT06608511","Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers",[],"2026-08-03T02:07:36.529363Z","2026-05-13T02:55:06.554644Z",[281,285,289],{"biomarker":282,"count":283,"slug":284},"Soluble Epidermal Growth Factor Receptor",4,"soluble-epidermal-growth-factor-receptor",{"biomarker":286,"count":287,"slug":288},"BRAF Gene",3,"braf-gene",{"biomarker":290,"count":287,"slug":291},"MRC1 wt Allele","mrc1-wt-allele",[293,297,301,305,309,313,316,320,323,326,329,332,336,339,342,345,348,351,354,357,360,363,366],{"state":294,"count":295,"slug":296},"Texas",17,"texas",{"state":298,"count":299,"slug":300},"California",15,"california",{"state":302,"count":303,"slug":304},"Florida",14,"florida",{"state":306,"count":307,"slug":308},"Massachusetts",11,"massachusetts",{"state":310,"count":311,"slug":312},"New York",10,"new-york",{"state":314,"count":311,"slug":315},"Pennsylvania","pennsylvania",{"state":317,"count":318,"slug":319},"Arizona",6,"arizona",{"state":321,"count":318,"slug":322},"Georgia","georgia",{"state":324,"count":318,"slug":325},"Michigan","michigan",{"state":327,"count":318,"slug":328},"New Jersey","new-jersey",{"state":330,"count":318,"slug":331},"Ohio","ohio",{"state":333,"count":334,"slug":335},"Illinois",5,"illinois",{"state":337,"count":334,"slug":338},"Indiana","indiana",{"state":340,"count":334,"slug":341},"North Carolina","north-carolina",{"state":343,"count":334,"slug":344},"Virginia","virginia",{"state":346,"count":283,"slug":347},"Missouri","missouri",{"state":349,"count":283,"slug":350},"Tennessee","tennessee",{"state":352,"count":283,"slug":353},"Utah","utah",{"state":355,"count":287,"slug":356},"Maryland","maryland",{"state":358,"count":287,"slug":359},"Minnesota","minnesota",{"state":361,"count":287,"slug":362},"Oklahoma","oklahoma",{"state":364,"count":287,"slug":365},"Oregon","oregon",{"state":367,"count":287,"slug":368},"Wisconsin","wisconsin"]